Patient advocacy groups play many roles in orphan drug development, including funding and propelling early development and interacting with key stakeholders such as the patients, their caregivers, regulatory bodies, elected officials, and payers. By engaging with these organizations throughout the drug development process, drug developers may have a smoother development path and be able to launch new therapies for these rare diseases faster.
How do patient advocacy groups support research & development efforts in the rare disease space? How can biopharma companies support these endeavors?
How do patient advocacy groups interact with key industry stakeholders?
How can biopharma companies support nascent advocacy groups, and how should they engage established organizations?
- Rare Diseases And Orphan Drugs - Access & Reimbursement - Special Topics: Partnering With Patient Advocacy Groups To Accelerate Orphan Drug Development (US)
Author(s): Claudia Dall'Osso
Claudia is a Senior Business Insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing on niche and rare indications.
Before joining DRG, she held a management and strategy consultant position at Precision Medicine Group, where she worked for clients in the biopharmaceutical, medical device and diagnostic industries. Claudia completed her Master’s in Management at Harvard University; she also holds a Ph.D. in medical genetics from Brescia University in Italy and a BS/MS degree in medical biotechnology from University of Milano in Italy.